-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s Tirofiban Hydrochloride Injection Concentrate (15 ml) Has Been Approved.
Category:
Time：2023-06-30
On June 29, the concentrated solution for intravenous injection of tirofiban hydrochloride (15 ml), submitted by Shijiazhuang Fourth Pharmaceutical Group, received drug production registration approval from the National Medical Products Administration and is deemed to have passed the evaluation of consistency in quality and efficacy for generic drugs. This is the group’s 34th new product approved so far this year.
On June 29, the concentrated solution for intravenous injection of tirofiban hydrochloride (15 ml), submitted by Shijiazhuang Fourth Pharmaceutical Group, received drug production registration approval from the National Medical Products Administration and is deemed to have passed the evaluation of quality and efficacy consistency for generic drugs. This is the group’s 34th new product approved so far this year.
It is reported that tirofiban hydrochloride injection concentrate is an antiplatelet agent clinically indicated for adult patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) who experienced their last episode of chest pain within 12 hours and exhibit ECG changes and/or elevated cardiac enzymes, to prevent early myocardial infarction.
In recent years, Shijiazhuang No.4 Pharmaceutical Group has cultivated fertile ground for technological innovation, yielding abundant innovative achievements. As of now, 51 varieties comprising 67 specifications of products have either passed or been deemed to have passed the national evaluation for consistency in quality and efficacy of generic drugs.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license